Share on
Identification of two novel LDLR variants by Next Generation Sequencing
Abstract
Methods. We report two patients: a 48-year-old Asian woman, without known history of hypercholesterolemia and a 46-year-old Caucasian man, with childhood hypercholesterolemia.
Results. An effective NGS-based pipeline, FH-Devyser kit/Amplicon Suite, beginning from sequencing to data analysis, did not identify known PVs in the LDLR, APOB, APOE, LDLRAP1, STAP1 and PCSK9 genes, but revealed two novel LDLR variants (c.1564A>T, p.Ile522Phe and c.1688C>T, p.Pro563Leu).
Discussion and conclusions. This study showed that an effective NGS-based pipeline led to a definitive diagnosis in two FH families, allowing to plan their therapeutic treatment. Although the functional consequence of the two LDLR variants needs to be assessed in vitro, the in silico analysis and high preservation of the two amino acid positions observed in the LDLR protein, across different animal species, suggest that both variants are deleterious.
Downloads
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Moffa, S., Mazzuccato, G., De Bonis, M., De Paolis, E., Onori, M. E., Pontecorvi, A., Urbani, A., Giaccari, A., Capoluongo, E., & Minucci, A. (2020). Identification of two novel LDLR variants by Next Generation Sequencing. Annali dell’Istituto Superiore Di Sanità, 56(1), 122–127. Retrieved from https://annali.iss.it/index.php/anna/article/view/895
- Abstract viewed - 592 times
- PDF downloaded - 218 times